新型疫苗可在老鼠體內100%對抗惡性黑色素瘤

A new cancer vaccine has shown a 100 percent success rate when treating aggressive melanoma in mice.

一種新型癌症疫苗，目前已經能夠100%成功治療老鼠身體內的惡性黑色素瘤。

Researchers at Scripps Research Institute in La Jolla, Calif., and the University of Texas in Dallas, gave mice suffering from melanoma a cancer immunotherapy drug called anti-PD-L1, which prevents tumor cells from attacking their immune systems.

加州拉霍亞市斯克裏普斯研究所和達拉斯德州大學的研究人員給患有黑色素瘤的老鼠注射了一種名爲PD-L1的癌症免疫治療藥物，這種藥物可以防止腫瘤細胞攻擊它們的免疫系統。

The study found that rodents who were also given Diprovocim, a chemical compound that's meant to galvanize the immune system, had a 100 percent survival rate.

研究發現，同時被注射一種叫Diprovocim的化學物質的老鼠有100%的存活率，Diprovocim可以刺激免疫系統。

And attempts to re-introduce cancer tumors in these vaccinated mice failed.

而且被接種疫苗的老鼠沒法再被重新引入癌症腫瘤。

While more research needs to be done to determine the vaccine's effectiveness in humans, researchers are hopeful about their findings.

雖然還需要做更多的研究來確定疫苗是否對人類有效，但研究人員對他們的發現充滿希望。

"Just as a vaccine can train the body to fight off external pathogens, this vaccine trains the immune system to go after the tumor," Dale Boger, a chemist at Scripps, wrote in a press release.

斯克裏普斯的化學家戴爾·博格在一份新聞稿中寫道：“就像疫苗可以訓練身體抵抗外部病原體一樣，這種疫苗也可以訓練免疫系統去對付腫瘤。”

"This co-therapy produced a complete response -- a curative response -- in the treatment of melanoma."

“這種聯合治療在治療黑素瘤中產生了完全緩解，即治療反應。”

According to the American Cancer Society, more than 9,000 people die of melanoma every year, and it accounts for about 1 percent of skin cancer diagnoses in the US.

據美國癌症協會統計，每年有9000多人死於黑素瘤。而在美國診斷出的皮膚癌患中，黑素瘤約佔其中的1%。